Compliance Radar

Who was sanctioned, and for what?

Fines, court rulings and incidents from Europe, North America, Latin America, Asia-Pacific, Middle East and Africa: 2,207 cases from 44 jurisdictions, each with an official source and checked against that source before publication. Filter by country, area of law and sector. Click a chart to drill down one level.

16cases from 1 jurisdiction
€5.27bnTotal of monetary amounts (13 cases with an amount)
€4.75bnLargest single case: Purdue Pharma L.P.
€18.8mMedian per case with an amount

Click a bar to drill down one level.

When?

per year, by date of decision
Trend
PeriodCasesTotal
20232€206.5m
20241€18.8m
20254€238.4m
20269€4.81bn

16 cases

10 Sep 2026 Dompé U.S. Inc.Dompé U.S.: 32 million USD – Medicare patients’ co-payments covered via foundations USAGifts, hospitality and benefits €27.5m

From 2018 to 2021, the pharmaceutical manufacturer allegedly used two patient assistance foundations to fund Medicare beneficiaries’ co-payments for its drug Oxervate in order to promote its sales. Following a self-disclosure, Dompé paid 32 million USD.

What organisations can take from it

Benefits flowing to customers via foundations or other third parties remain benefits provided by the company – donations to patient assistance programmes require strict independence.

Relevance to training and awareness

Benefits to patients and customers via third parties

Authority / court
U.S. Department of Justice / U.S. Attorney's Office, District of Massachusetts
Area of law
Bribery and corruption · Gifts, hospitality and benefits
Legal basis
Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)); False Claims Act (31 U.S.C. §§ 3729 ff.)
Action
Other
Status of proceedings
final
Sector
Chemicals and pharmaceuticals
Mitigating circumstances
Self-disclosure.

Original amount 32,000,000 USD, converted at the ECB reference rate of 10 Sep 2026.

Checked against the official source on 25 Sep 2026 · Direct link

Report an error

Anonymous: we store only your text, no contact details and no IP address.

14 Aug 2026 Henkel AG & Co. KGaAHenkel/Liquid Nails: court blocks takeover of Loctite’s main competitor USAMerger control Order

Henkel wanted to buy the construction adhesive brand Liquid Nails for 725 million USD from the financial investor American Industrial Partners, thereby taking over the main competitor of its Loctite brand. After a seven-day trial, the federal court, on application by the Federal Trade Commission (FTC), issued a permanent injunction against the acquisition.

What organisations can take from it

Acquiring the closest competitor carries a high risk of prohibition, even at a moderate deal volume.

Authority / court
U.S. District Court for the Southern District of New York (auf Antrag der FTC)
Area of law
Competition law · Merger control
Legal basis
Section 7 Clayton Act; Section 13(b) FTC Act (Permanent Injunction)
Action
Order
Status of proceedings
unknown
Sector
Chemicals and pharmaceuticals
Employees
10,000 or more
Published
17 Aug 2026

Checked against the official source on 25 Sep 2026 · Direct link

Report an error

Anonymous: we store only your text, no contact details and no IP address.

10 Aug 2026 Veloxis Pharmaceuticals Inc.Veloxis: over 46 million USD – luxury trips, dinners and gifts for transplant teams USAGifts, hospitality and benefits Other

From 2016 to 2023, Veloxis provided transplant professionals with expensive meals and alcohol, trips and stays at luxury resorts, gifts and consultancy fees without consideration, and paid specialty pharmacies concealed remuneration in order to promote prescriptions and purchases of the immunosuppressant Envarsus XR. The company entered into a Deferred Prosecution Agreement with a criminal payment of more than 10 million USD, is paying 34.45 million USD under civil law (21,211,251 USD to the federal government, 13,238,749 USD to states) and a penalty of 1.55 million USD under the Sunshine Act (Open Payments) – the highest to date – totalling over 46 million USD.

What organisations can take from it

Invitations and gifts to decision-makers must not only be limited but also fully reported to transparency registers.

Relevance to training and awareness

Gifts, travel and hospitality for healthcare professionals; transparency reporting

Authority / court
U.S. Department of Justice / U.S. Attorney's Office, District of Massachusetts
Area of law
Bribery and corruption · Gifts, hospitality and benefits
Legal basis
Anti-Kickback Statute; False Claims Act; Physician Payments Sunshine Act (Open Payments)
Action
Other
Status of proceedings
final
Sector
Chemicals and pharmaceuticals

Checked against the official source on 25 Sep 2026 · Direct link

Report an error

Anonymous: we store only your text, no contact details and no IP address.

3 Aug 2026 Guangxi Kelun Pharmaceutical Co., Ltd.UFLPA list: antibiotics manufacturer Guangxi Kelun Pharmaceutical added USAForced and child labour Order

The U.S. Forced Labor Enforcement Task Force (FLETF) listed the manufacturer of cephalosporin antibiotics because it sources antibiotic intermediates from Yili Chuanning Biotechnology in Xinjiang. The company's goods are therefore presumed to have been produced with forced labour on import into the US unless the importer rebuts this.

What organisations can take from it

Pharmaceutical companies must be able to trace their supply chains back to active ingredient intermediates.

Authority / court
U.S. Department of Homeland Security (Forced Labor Enforcement Task Force)
Area of law
Supply chain and human rights · Forced and child labour
Legal basis
Uyghur Forced Labor Prevention Act, Section 2(d)(2)(B)(v)
Action
Order
Status of proceedings
unknown
Sector
Chemicals and pharmaceuticals
Published
3 Aug 2026

Checked against the official source on 25 Sep 2026 · Direct link

Report an error

Anonymous: we store only your text, no contact details and no IP address.

20 Jul 2026 EyePoint Pharmaceuticals, Inc.EyePoint: 4.66 million USD – kickbacks to surgery centres for purchasing an eye medicine USACommercial bribery €4.08m

Between January 2019 and March 2023, the pharmaceutical manufacturer allegedly paid kickbacks to ambulatory surgery centres to induce them to purchase and use the injectable drug DEXYCU for cataract surgery. To resolve the False Claims Act allegations, EyePoint paid 4,657,463.18 USD and entered into a Corporate Integrity Agreement with HHS-OIG.

What organisations can take from it

Discounts, payments or services to institutions that make purchasing decisions require a documented consideration at market value.

Relevance to training and awareness

Granting benefits to customers and purchasing decision-makers

Authority / court
U.S. Department of Justice
Area of law
Bribery and corruption · Commercial bribery
Legal basis
Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)); False Claims Act (31 U.S.C. §§ 3729 ff.)
Action
Other
Status of proceedings
final
Sector
Chemicals and pharmaceuticals

Original amount 4,657,463.18 USD, converted at the ECB reference rate of 20 Jul 2026.

Checked against the official source on 25 Sep 2026 · Direct link

Report an error

Anonymous: we store only your text, no contact details and no IP address.

24 Jun 2026 The Chemours Company; The Chemours Company FC, LLCChemours: USD 22.5m civil penalty in PFAS settlement with EPA and West Virginia USAEmissions and permits €19.8m

The EPA, the US Department of Justice and West Virginia's environmental agency reached a settlement (consent decree) with Chemours over PFAS discharges into the Cape Fear, Delaware and Ohio rivers, some made without and some in breach of discharge permits, together with TSCA and RCRA violations at four plants. Chemours will pay a civil penalty of 22,500,000 USD in three annual instalments of 7,500,000 USD and carry out remedial measures, including drinking water supply, PFAS controls and a USD 90m mitigation programme, which the EPA puts at over USD 450m in total. The settlement was lodged with the court on 24 June 2026 and is subject to public comment and court approval. The authority allegedly made the findings set out here; this account is not based on a final judgment. The decision is not final.

What organisations can take from it

PFAS manufacturers must continuously check every discharge against their permits – unregulated flows lead to penalties and costly obligations towards local residents.

Relevance to training and awareness

Discharge permits and PFAS emissions

Authority / court
U.S. Environmental Protection Agency (EPA) / U.S. Department of Justice mit West Virginia Department of Environmental Protection (U.S. District Court, Southern District of West Virginia)
Area of law
Environment and sustainability · Emissions and permits
Legal basis
Clean Water Act (NPDES); Resource Conservation and Recovery Act; Toxic Substances Control Act; West Virginia Water Pollution Control Act
Action
Fine
Status of proceedings
not yet final
Sector
Chemicals and pharmaceuticals
Mitigating circumstances
The civil penalty was set on the basis of the company's ability to pay.
Published
24 Jun 2026

Original amount 22,500,000 USD, converted at the ECB reference rate of 24 Jun 2026.

Checked against the official source on 3 Oct 2026 · Direct link

Report an error

Anonymous: we store only your text, no contact details and no IP address.

23 Jun 2026 Denka Performance Elastomer, LLCDenka Performance Elastomer: USD 996,703 over hazardous waste at neoprene plant USAWaste and hazardous substances €874,915

The EPA (Region 6) issued a Consent Agreement and Final Order against Denka Performance Elastomer over RCRA violations at its neoprene plant in LaPlace (Louisiana): missing waste determinations, breaches of land disposal restrictions and treatment and storage of hazardous waste without a permit. Denka will pay 996,703.35 USD and must clean out a brine pit and its ancillary equipment; if the currently idle plant resumes operations, further requirements apply, including on waste inventory, containers, training and protective equipment. The authority allegedly made the findings set out here; this account is not based on a final judgment.

What organisations can take from it

Every waste stream needs a documented determination of whether it is hazardous – without it there is no basis for lawful storage, treatment and disposal.

Relevance to training and awareness

Classification and storage of hazardous waste

Missing or inadequate training played a role in the decision.

Authority / court
U.S. Environmental Protection Agency (EPA), Region 6
Area of law
Environment and sustainability · Waste and hazardous substances
Legal basis
Resource Conservation and Recovery Act (RCRA), Docket RCRA-06-2025-0910
Action
Fine
Status of proceedings
final
Sector
Chemicals and pharmaceuticals
Repeat case
yes
Published
2 Jul 2026

Original amount 996,703.35 USD, converted at the ECB reference rate of 23 Jun 2026.

Checked against the official source on 3 Oct 2026 · Direct link

Report an error

Anonymous: we store only your text, no contact details and no IP address.

14 May 2026 Takeda Pharmaceuticals U.S.A., Inc.Takeda: 13.7 million USD – speaker fees and luxury meals for prescribing physicians USAGifts, hospitality and benefits €11.7m

From 2014 to 2020, Takeda allegedly selected physicians specifically for its speaker programme for the antidepressant Trintellix and provided them with fees and meals at expensive restaurants to promote prescriptions; some participants attended the same event several times without any educational benefit. Takeda paid 13,670,921 USD.

What organisations can take from it

Speaker programmes need a demonstrable educational purpose – repeated attendance and expensive hospitality turn them into inducements.

Relevance to training and awareness

Invitations, hospitality and fees for healthcare professionals

Authority / court
U.S. Department of Justice / U.S. Attorney's Office, Eastern District of California
Area of law
Bribery and corruption · Gifts, hospitality and benefits
Legal basis
Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)); False Claims Act (31 U.S.C. §§ 3729 ff.)
Action
Other
Status of proceedings
final
Sector
Chemicals and pharmaceuticals
Employees
10,000 or more

Original amount 13,670,921 USD, converted at the ECB reference rate of 14 May 2026.

Checked against the official source on 25 Sep 2026 · Direct link

Report an error

Anonymous: we store only your text, no contact details and no IP address.

28 Apr 2026 Purdue Pharma L.P.Purdue Pharma: 5.544 billion USD penalty – including kickbacks via the speaker programme USAGifts, hospitality and benefits €4.75bn

Following its 2020 guilty plea, the opioid manufacturer was sentenced in Newark to a criminal fine of 3.544 billion USD (asserted in the insolvency proceedings) and forfeiture of 2 billion USD; up to 1.775 billion USD can be credited against the forfeiture if Purdue emerges from insolvency as a public benefit company. Purdue had deceived the DEA and paid kickbacks to prescribers via its speaker programme and to an electronic health records platform in order to increase opioid prescriptions.

What organisations can take from it

Fee programmes for customers who drive revenue can become part of a criminal overall scheme – with consequences that threaten the company’s existence.

Relevance to training and awareness

Speaker fees and benefits for prescribing physicians

Authority / court
U.S. District Court, District of New Jersey (Anklage: U.S. Department of Justice)
Area of law
Bribery and corruption · Gifts, hospitality and benefits
Legal basis
Verschwörung zum Betrug der USA und zur Verletzung des Food, Drug, and Cosmetic Act; zwei Fälle Verschwörung zur Verletzung des Anti-Kickback Statute (Schuldbekenntnis vom 24.11.2020)
Action
Fine
Status of proceedings
unknown
Sector
Chemicals and pharmaceuticals
Culpability
intentional

Original amount 5,544,000,000 USD, converted at the ECB reference rate of 28 Apr 2026.

Checked against the official source on 25 Sep 2026 · Direct link

Report an error

Anonymous: we store only your text, no contact details and no IP address.

16 Jun 2025 Unicat Catalyst Technologies, LLCCatalyst manufacturer Unicat supplied Iran and blocked Venezuelan company USABreaches of sanctions and embargoes €3.35m

In 2016–2021, the Texas supplier of catalysts for refineries and steelworks supplied products and advice to customers in Iran via employees and agents, and sold goods to a blocked Venezuelan company. The US Treasury's Office of Foreign Assets Control (OFAC) considered it an egregious but voluntarily self-disclosed case; there were parallel settlements with the DOJ and BIS, which were taken into account in determining the amount.

What organisations can take from it

When senior management itself steers embargo business, only independent controls and whistleblower channels help – voluntary self-disclosure after discovery reduces the penalty but does not prevent it.

Authority / court
U.S. Department of the Treasury, Office of Foreign Assets Control (OFAC)
Area of law
Sanctions and export control · Breaches of sanctions and embargoes
Legal basis
Iranian Transactions and Sanctions Regulations; Venezuela Sanctions Regulations; IEEPA
Action
Fine
Status of proceedings
final
Sector
Chemicals and pharmaceuticals
Culpability
intentional
Mitigating circumstances
Voluntary self-disclosure, cooperation and remedial measures after discovery
Liability of senior managers
Measures against individuals are not reported here.
Published
16 Jun 2025

Original amount 3,882,797 USD, converted at the ECB reference rate of 16 Jun 2025.

Checked against the official source on 28 Sep 2026 · Version 2 · Direct link

Report an error

Anonymous: we store only your text, no contact details and no IP address.

28 Apr 2025 Gilead Sciences, Inc.Gilead: 202 million USD – speaker programmes with fees, luxury meals and travel USAGifts, hospitality and benefits €177.8m

Gilead paid physicians who spoke at or attended events on its HIV medicines fees, meals and travel expenses to promote prescriptions; high prescribers received hundreds of thousands of dollars, and events took place at luxury restaurants. The court-approved settlement of 202 million USD contains extensive admissions of fact.

What organisations can take from it

Selecting speakers by prescription volume turns continuing education into bribery – selection criteria and hospitality limits must be documented.

Relevance to training and awareness

Fees and hospitality at professional events

Authority / court
U.S. Attorney's Office, Southern District of New York; U.S. District Court (S.D.N.Y.)
Area of law
Bribery and corruption · Gifts, hospitality and benefits
Legal basis
Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)); False Claims Act (31 U.S.C. §§ 3729 ff.)
Action
Other
Status of proceedings
final
Sector
Chemicals and pharmaceuticals
Employees
10,000 or more
Published
29 Apr 2025

Original amount 202,000,000 USD, converted at the ECB reference rate of 28 Apr 2025.

Checked against the official source on 25 Sep 2026 · Direct link

Report an error

Anonymous: we store only your text, no contact details and no IP address.

24 Jan 2025 Pfizer Inc. (für die Tochter Biohaven Pharmaceutical Holding Company Ltd.)Pfizer/Biohaven: USD 59.7m over speaker fees and lavish meals for doctors USAGifts, hospitality and benefits €57.1m

Pfizer pays USD 59,746,277 on behalf of its subsidiary Biohaven to resolve False Claims Act and Anti-Kickback Statute allegations relating to the period before the acquisition; about USD 50.2 million goes to the federal government and about USD 9.5 million to state Medicaid programmes. From March 2020 to September 2022 Biohaven allegedly gave selected doctors speaker fees and meals at expensive restaurants to encourage prescriptions of the migraine drug Nurtec ODT; some events were attended repeatedly by the same doctors or by spouses, relatives and practice colleagues with no educational need.

What organisations can take from it

In acquisitions, the target's speaker programmes and payments to doctors belong in due diligence – the liability passes to the buyer.

Relevance to training and awareness

Speaker programmes: selection of speakers, repeat attendance, hospitality

Authority / court
U.S. Department of Justice (Civil Division; USAO Western District of New York)
Area of law
Bribery and corruption · Gifts, hospitality and benefits
Legal basis
False Claims Act; Anti-Kickback Statute
Action
Other
Status of proceedings
final
Sector
Chemicals and pharmaceuticals
Employees
10,000 or more
Published
24 Jan 2025

Original amount 59,746,277 USD, converted at the ECB reference rate of 24 Jan 2025.

Checked against the official source on 3 Oct 2026 · Direct link

Report an error

Anonymous: we store only your text, no contact details and no IP address.

14 Jan 2025 AFCO (Tochtergesellschaft der Zep Inc.)Zep subsidiary AFCO: $161,310 proposed after nitrogen dioxide release USAWorkplace safety and accidents €157,452

In July 2024, nitrogen dioxide above the exposure limit was released during chemical processing at the plant of Zep subsidiary AFCO in Chambersburg (Pennsylvania); twelve employees were examined in hospital and two were admitted. The U.S. Occupational Safety and Health Administration (OSHA) criticised the lack of an emergency action plan, deficient respiratory protection and hazard communication programmes and a delayed evacuation, and proposed $161,310 (including one repeat violation).

What organisations can take from it

In the event of a chemical release, a rehearsed emergency and evacuation plan determines how many employees come to harm.

Relevance to training and awareness

Responding to gas releases and evacuation

Authority / court
U.S. Department of Labor – Occupational Safety and Health Administration (OSHA)
Area of law
Health and safety and employment law · Workplace safety and accidents
Legal basis
29 CFR 1910.120, 1910.134, 1910.1200
Action
Fine
Status of proceedings
unknown
Sector
Chemicals and pharmaceuticals
Repeat case
yes
Published
14 Jan 2025

Original amount 161,310 USD, converted at the ECB reference rate of 14 Jan 2025.

Checked against the official source on 25 Sep 2026 · Direct link

Report an error

Anonymous: we store only your text, no contact details and no IP address.

19 Apr 2024 a Thai plastics companyThai plastics company pays 20 million USD for concealed sales of Iranian polyethylene USABreaches of sanctions and embargoesanonymised €18.8m

In 2017–2018, the Thai plastics company had US banks process 467 payments totalling 291 million USD for HDPE plastic produced in an Iranian joint venture with the Iranian state-owned petrochemical group. Shipping and documentation practices concealed the Iranian origin. The penalty was imposed by the US Treasury's Office of Foreign Assets Control (OFAC).

What organisations can take from it

Invoicing in US dollars brings US sanctions law into the business – holdings in embargoed countries require strict separation of payment flows.

Authority / court
U.S. Department of the Treasury, Office of Foreign Assets Control (OFAC)
Area of law
Sanctions and export control · Breaches of sanctions and embargoes
Legal basis
Iranian Transactions and Sanctions Regulations (31 C.F.R. part 560)
Action
Fine
Status of proceedings
final
Sector
Chemicals and pharmaceuticals
Culpability
intentional
Published
19 Apr 2024

Original amount 20,000,000 USD, converted at the ECB reference rate of 19 Apr 2024.

Checked against the official source on 28 Sep 2026 · Version 4 · Company name anonymised since 19 Apr 2026 · Direct link

Report an error

Anonymous: we store only your text, no contact details and no IP address.

8 Sep 2023 a US cleantech companySEC: US cleantech firm pays 225,000 US dollars over award waivers USARetaliation against whistleblowersanonymised €210,202

From February 2020 to March 2023, the unlisted cleantech company (around 236 employees) had 22 departing employees waive awards for reports to authorities. After contact by the U.S. Securities and Exchange Commission (SEC), the company amended the agreements and informed those affected; the penalty amounted to 225,000 US dollars.

What organisations can take from it

Unlisted companies are also subject to the SEC's whistleblower protection rules.

Relevance to training and awareness

Whistleblower protection in contract templates (HR/Legal)

Authority / court
U.S. Securities and Exchange Commission
Area of law
Whistleblower protection · Retaliation against whistleblowers
Legal basis
Securities Exchange Act of 1934, Rule 21F-17(a)
Action
Fine
Status of proceedings
final
Sector
Chemicals and pharmaceuticals
Employees
50 to 249
Mitigating circumstances
Revision of the separation agreements and information provided to the former employees affected
Published
8 Sep 2023

Original amount 225,000 USD, converted at the ECB reference rate of 8 Sep 2023.

Checked against the official source on 28 Sep 2026 · Version 4 · Company name anonymised since 8 Sep 2025 · Direct link

Report an error

Anonymous: we store only your text, no contact details and no IP address.

21 Aug 2023 a US generic drug manufacturerDOJ: generics manufacturer pays 225 million USD criminal penalty over generic drug price fixing USACartels and collusionanonymised €206.3m

In a Deferred Prosecution Agreement, the manufacturer admitted to three conspiracies involving price fixing, customer allocation and bid rigging for generic drugs (including pravastatin). The manufacturer is paying a criminal penalty of 225 million USD in instalments, donating medicines worth 50 million USD and must divest its pravastatin business under the supervision of a monitor.

What organisations can take from it

In addition to penalties running into millions, antitrust violations can force companies to divest entire product lines.

Relevance to training and awareness

Agreements among generic drug manufacturers on prices and customers

Authority / court
U.S. Department of Justice, Antitrust Division
Area of law
Competition law · Cartels and collusion
Legal basis
15 U.S.C. § 1 (Sherman Act)
Action
Fine
Status of proceedings
unknown
Sector
Chemicals and pharmaceuticals
Employees
10,000 or more

Original amount 225,000,000 USD, converted at the ECB reference rate of 21 Aug 2023.

Checked against the official source on 28 Sep 2026 · Version 4 · Company name anonymised since 21 Aug 2025 · Direct link

Report an error

Anonymous: we store only your text, no contact details and no IP address.

Ready for training that actually lands?

Try the combination for free: automated administration for you, learning formats that fit your team, with no minimum or credit card.

Start 14-day free trial